Market Cap | 62.47M | P/E | - | EPS this Y | 97.70% | Ern Qtrly Grth | - |
Income | 15.79M | Forward P/E | -0.84 | EPS next Y | -1,691.70% | 50D Avg Chg | -16.00% |
Sales | 87.64M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -45.00% |
Dividend | N/A | Price/Book | 1.55 | EPS next 5Y | - | 52W High Chg | -74.00% |
Recommedations | 1.80 | Quick Ratio | 3.80 | Shares Outstanding | 7.23M | 52W Low Chg | 7.00% |
Insider Own | 6.78% | ROA | -2.62% | Shares Float | 5.72M | Beta | 1.69 |
Inst Own | 45.00% | ROE | 29.04% | Shares Shorted/Prior | 234.33K/255.22K | Price | 0.55 |
Gross Margin | 100.00% | Profit Margin | 19.36% | Avg. Volume | 757,020 | Target Price | 33.60 |
Oper. Margin | 48.39% | Earnings Date | Nov 5 | Volume | 1,172,449 | Change | -5.28% |
Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
HC Wainwright & Co. | Buy | May 30, 24 |
HC Wainwright & Co. | Buy | May 16, 24 |
Guggenheim | Buy | Apr 30, 24 |
HC Wainwright & Co. | Buy | Apr 17, 24 |
HC Wainwright & Co. | Buy | Mar 28, 24 |
HC Wainwright & Co. | Buy | Feb 14, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Amoroso Michael | President and CEO President and CEO | Jan 20 | Sell | 0.36 | 137,390 | 49,460 | 356,433 | 01/23/24 |
Scimeca Dario | General Counsel and.. General Counsel and Secretary | Jan 20 | Sell | 0.36 | 21,287 | 7,663 | 151,028 | 01/23/24 |
List Alan | Chief Medical Office.. Chief Medical Officer | Jan 20 | Sell | 0.36 | 21,526 | 7,749 | 94,982 | 01/23/24 |
SMITH J. JEFFERSON | Chief Research Offic.. Chief Research Officer | Jan 20 | Sell | 0.37 | 28,000 | 10,360 | 1,987,269 | 01/23/24 |
Kelly John Alexander | Chief Financial Offi.. Chief Financial Officer | Aug 18 | Buy | 0.48 | 90,000 | 43,200 | 383,340 | 10/27/23 |
List Alan | Chief Medical Office.. Chief Medical Officer | Apr 26 | Sell | 0.79 | 7,771 | 6,139 | 56,496 | 04/28/23 |
Kelly John Alexander | Chief Financial Offi.. Chief Financial Officer | Mar 17 | Buy | 0.86 | 20,000 | 17,200 | 245,614 | 03/21/23 |
Kelly John Alexander | Chief Financial Offi.. Chief Financial Officer | Jun 22 | Buy | 1.50 | 33,784 | 50,676 | 117,701 | 06/24/22 |
Scimeca Dario | General Counsel and.. General Counsel and Secretary | Jun 07 | Sell | 2.06 | 9,833 | 20,256 | 32,514 | 06/09/22 |
List Alan | Chief Medical Office.. Chief Medical Officer | Apr 26 | Sell | 2.1 | 7,775 | 16,328 | 18,260 | 04/28/22 |
Kelly John Alexander | Chief Financial Offi.. Chief Financial Officer | Mar 17 | Buy | 3.08 | 16,677 | 51,365 | 36,189 | 03/21/22 |
THOMSON DAVID S. | Chief Operating Offi.. Chief Operating Officer | Jun 23 | Option | 1.18 | 15,000 | 17,700 | 126,513 | 06/23/21 |
THOMSON DAVID S. | Chief Operating Offi.. Chief Operating Officer | Jun 23 | Sell | 10.77 | 15,000 | 161,550 | 111,513 | 06/23/21 |
KANE MATTHEW R. | President and CEO President and CEO | Apr 12 | Option | 0.04 | 43,028 | 1,721 | 1,962,760 | 04/12/21 |
JANTZ DEREK | Chief Scientific Off.. Chief Scientific Officer | Feb 22 | Option | 0.04 | 43,028 | 1,721 | 3,943,502 | 02/22/21 |
JANTZ DEREK | Chief Scientific Off.. Chief Scientific Officer | Feb 22 | Sell | 11.88 | 16,534 | 196,424 | 3,933,839 | 02/22/21 |